GlassScriptPhysician profile
Balesh Sharma
NPI 1578505483
$7,896.28
in general payments reported to CMS, 2019-2025
47 companies · $1,603 in 2025
The $1,603 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,074 · 2020: $225 · 2021: $151 · 2022: $1,287 · 2023: $2,004 · 2024: $1,552 · 2025: $1,603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,855 · Education: $304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,855.49 |
| Education | $303.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $970.83 | 2019-2025 | Opdivo, Breyanzi, Reblozyl |
| Eisai INC. | $674.76 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $661.23 | 2019-2025 | Lynparza, Tagrisso, Enhertu |
| Janssen Biotech, INC. | $616.19 | 2019-2025 | Rybrevant, Carvykti, Darzalex |
| Merck Sharp & Dohme LLC | $484.62 | 2019-2025 | Lynparza, Keytruda, Lenvima |
| Genentech USA, INC. | $307.98 | 2019-2025 | Tecentriq, Polivy, Tecentriq Hybreza |
| Lilly USA, LLC | $297.82 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Pfizer INC. | $274.64 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $227.98 | 2023-2025 | Libtayo |
| Sumitomo Pharma America, INC. | $196.18 | 2023-2025 | Orgovyx |
| Celgene Corporation | $174.28 | 2022-2025 | Opdualag, Reblozyl, Pomalyst |
| Karyopharm Therapeutics INC. | $170.55 | 2023-2024 | Xpovio |
| Novartis Pharmaceuticals Corporation | $170.39 | 2022-2025 | |
| Glaxosmithkline, LLC. | $166.60 | 2023-2025 | Ojjaara |
| Daiichi Sankyo INC. | $155.34 | 2024-2025 | Enhertu |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Balesh Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.